Carfilzomib
- Generic Name
- Carfilzomib
- Brand Names
- Kyprolis
- Drug Type
- Small Molecule
- Chemical Formula
- C40H57N5O7
- CAS Number
- 868540-17-4
- Unique Ingredient Identifier
- 72X6E3J5AR
- Background
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.
- Indication
Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
- Associated Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM)
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: FDG-Positron Emission Tomography
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT06948084
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
- Conditions
- Kidney Transplant Rejection
- Interventions
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Target Recruit Count
- 100
- Registration Number
- NCT06918990
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 440
- Registration Number
- NCT06892522
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
- Conditions
- Extramedullary Multiple Myeloma
- Interventions
- Biological: anti-BCMA/GPRC5D bispecific CAR-TDrug: Apornemin
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-03-13
- Target Recruit Count
- 20
- Registration Number
- NCT06793475
- Locations
- 🇨🇳
Beijing Gobroad Boren Hospital, Beijing, China
🇨🇳Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, China
Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
- First Posted Date
- 2024-11-11
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 50
- Registration Number
- NCT06682156
- Locations
- 🇨🇳
Lingzhi Yan, Suzhou, Jiangsu, China
Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease
- Conditions
- Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: EchocardiographyProcedure: Positron Emission TomographyProcedure: Computed TomographyProcedure: Computed Tomography Assisted BiopsyProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Biospecimen Collection
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 28
- Registration Number
- NCT06627751
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Drug: Cxcr1/2 Inhibitor SX-682Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: EchocardiographyProcedure: Positron Emission TomographyProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT06622005
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma (QUINTESSENTIAL-2)
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Interventions
- First Posted Date
- 2024-09-26
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 440
- Registration Number
- NCT06615479
- Locations
- 🇺🇸
Local Institution - 0071, Birmingham, Alabama, United States
🇺🇸UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸Local Institution - 0130, Miami, Florida, United States
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Conditions
- Newly DiagnosedHigh RiskMRDMultiple Myeloma
- Interventions
- Drug: VRD for first-cycle induction therapy
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- The First Affiliated Hospital of Soochow University
- Target Recruit Count
- 45
- Registration Number
- NCT06409702
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.